Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.

Abstract:

:Patients with chronic hepatitis B (HBsAg-positive) are at risk of viral reactivation if rituximab is administered without antiviral treatment, a potentially fatal complication of treatment. Patients with so-called 'resolved hepatitis B virus infection' (HBsAg-negative/cAb-positive) may also be at risk. We performed a systematic review of the English and Chinese language literature to estimate the risk of hepatitis B virus (HBV) reactivation in HBsAg-negative/cAb-positive patients receiving rituximab for lymphoma. A pooled risk estimate was calculated for HBV reactivation. The impact of HBsAb status and study design on reactivation rates was explored. Data from 578 patients in 15 studies were included. 'Clinical HBV reactivation', (ALT >3 × normal and either an increase in HBV DNA from baseline or HBsAg seroreversion), was estimated at 6.3% (I(2) = 63%, P = 0.006). Significant heterogeneity was detected. Reactivation rates were higher in prospective vs retrospective studies (14.2% vs 3.8%; OR = 4.39, 95% CI 0.83-23.28). Exploratory analyses found no effect of HBsAb status on reactivation risk (OR = 0.083; P = 0.151). Our meta-analysis confirms a measurable and potentially substantial risk of HBV reactivation in HBsAg-negative/cAb-positive patients exposed to rituximab. However, heterogeneity in the existing literature limits the generalizability of our findings. Large, prospective studies, with uniform definitions of HBV reactivation, are needed to clarify the risk of HBV reactivation in HBsAg-negative/cAb-positive patients.

journal_name

J Viral Hepat

authors

Mozessohn L,Chan KK,Feld JJ,Hicks LK

doi

10.1111/jvh.12402

subject

Has Abstract

pub_date

2015-10-01 00:00:00

pages

842-9

issue

10

eissn

1352-0504

issn

1365-2893

journal_volume

22

pub_type

杂志文章,meta分析,评审
  • The burden of hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.

    abstract::Cameroon is thought to have one of the highest prevalences of hepatitis C virus (HCV) infection in the world (4.9% among adults). A marked cohort effect exists in several communities where ≈50% of the elderly are infected. Better assessment of HCV distribution is needed for planning treatment programmes. We tested for...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12894

    authors: Njouom R,Siffert I,Texier G,Lachenal G,Tejiokem MC,Pépin J,Fontanet A

    更新日期:2018-08-01 00:00:00

  • Cross-sectional survey of the extent and indicators of hepatitis C virus infection in Houston Department of Health and Human Services' sexually transmitted disease clinics.

    abstract::To evaluate the prevalence and indicators of hepatitis C virus (HCV) infection in Houston and determine the effectiveness of targeted HCV screening in sexually transmitted disease (STD) clinics. We performed a cross-sectional survey in low-risk and high-risk groups in Houston. This included a blinded survey of HCV con...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00410.x

    authors: D'Souza G,Arafat R,Hwang L,Cunningham C,Shah S,Reynolds K

    更新日期:2003-03-01 00:00:00

  • Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.

    abstract::Treatment of chronic hepatitis B has been greatly improved by the use of lamivudine, but mutations occur in the polymerase region of hepatitis B virus (HBV) and lamivudine-resistant mutants frequently develop. The emergence of lamivudine-resistant strains of HBV is a problem for treating chronic hepatitis B using lami...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00559.x

    authors: Natsuizaka M,Hige S,Ono Y,Ogawa K,Nakanishi M,Chuma M,Yoshida S,Asaka M

    更新日期:2005-03-01 00:00:00

  • Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.

    abstract::Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three patients with cirrhosis (n=52) or fibrosing cholestatic hepatiti...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12712

    authors: Vukotic R,Conti F,Fagiuoli S,Morelli MC,Pasulo L,Colpani M,Foschi FG,Berardi S,Pianta P,Mangano M,Donato MF,Malinverno F,Monico S,Tamè M,Mazzella G,Belli LS,Viganò R,Carrai P,Burra P,Russo FP,Lenci I,Toniutto P

    更新日期:2017-10-01 00:00:00

  • Applicability and accuracy improvement of transient elastography using the M and XL probes by experienced operators.

    abstract::Transient elastography (TE) is the reference method to obtain liver stiffness measurements (LSM), but no results are obtained in 3.1% and unreliable in 15.8%. We assessed the applicability and diagnostic accuracy of TE re-evaluation using M and XL probes. From March 2011 to April 2012 868 LSM were performed with the M...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12296

    authors: Carrión JA,Puigvehí M,Coll S,Garcia-Retortillo M,Cañete N,Fernández R,Márquez C,Giménez MD,Garcia M,Bory F,Solà R

    更新日期:2015-03-01 00:00:00

  • Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment.

    abstract::Recently, attention has been focussed on adiponectin and its changes in different types of chronic liver disease. Its relation to hepatic fibrosis and insulin resistance in post-hepatitis liver disease is not clear. The aim of this study was to clarify the adiponectin changes in genotype 4 hepatitis C virus (HCV)-infe...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01096.x

    authors: Derbala M,Rizk N,Al-Kaabi S,Amer A,Shebl F,Al Marri A,Aigha I,Alyaesi D,Mohamed H,Aman H,Basem N

    更新日期:2009-10-01 00:00:00

  • Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis.

    abstract::The study was undertaken to investigate the features and clinical implications of hepatitis B virus (HBV) genotypes, basal core promoter (BCP) and precore (PC) mutations in hepatitis B-related acute-on-chronic liver failure (HB-ACLF). Samples from 75 patients with HB-ACLF and without pre-existing liver cirrhosis and 3...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01254.x

    authors: Ren X,Xu Z,Liu Y,Li X,Bai S,Ding N,Zhong Y,Wang L,Mao P,Zoulim F,Xu D

    更新日期:2010-12-01 00:00:00

  • Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.

    abstract::The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12838

    authors: Nam JY,Chang Y,Cho H,Kang SH,Cho YY,Cho EJ,Lee JH,Yu SJ,Yoon JH,Kim YJ

    更新日期:2018-05-01 00:00:00

  • In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.

    abstract::Only in a minority of patients with chronic hepatitis B (CHB) will treatment with interferon (IFN)-alpha or nucleoside analogues lead to sustained virological response. In vivo immunization (IVI) following virus suppression aims to optimize conditions for an effective immune response: following rapid and profound viru...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2007.00841.x

    authors: Sprengers D,van der Molen RG,Binda R,Kusters JG,de Man RA,Niesters HG,Schalm SW,Janssen HL

    更新日期:2007-10-01 00:00:00

  • Expression of interferon-alpha subtypes in peripheral mononuclear cells from patients with chronic hepatitis C: a role for interferon-alpha5.

    abstract::Interferon (IFN)-alpha is a family of antiviral proteins encoded by different genes. The biological significance of the existence of various IFN-alpha subtypes is not clear. We have investigated the interferon system in chronic hepatitis C virus (HCV) infection, a disease that responds to interferon-alpha2 therapy in ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2001.00273.x

    authors: Larrea E,Alberdi A,Castelruiz Y,Boya P,Civeira MP,Prieto J

    更新日期:2001-03-01 00:00:00

  • Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.

    abstract::Neumann et al. [1] developed a widely used model for the analysis of hepatitis C virus (HCV) dynamics after the initiation of interferon therapy that assumes the effectiveness of therapy in blocking virion production, epsilon, is constant. However, with pegylated interferon alpha-2b (PEG-IFN) given weekly, there are s...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00954.x

    authors: Shudo E,Ribeiro RM,Perelson AS

    更新日期:2008-05-01 00:00:00

  • Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium.

    abstract::In Italy, HDV infection endemicity has greatly decreased overtime. Migratory flow may change this scenario as migrants often come from high HDV endemicity areas. Here, we studied characteristics of HDV infection in Italy, particularly addressed to the birth area of subjects. Chronic HBsAg carriers consecutively referr...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13310

    authors: Stroffolini T,Ciancio A,Furlan C,Vinci M,Fontana R,Russello M,Colloredo G,Morisco F,Coppola N,Babudieri S,Ferrigno L,Sagnelli C,Sagnelli E

    更新日期:2020-09-01 00:00:00

  • Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.

    abstract::Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12664

    authors: Muñoz-Gómez R,Rincón D,Ahumada A,Hernández E,Devesa MJ,Izquierdo S,Ortiz M,Hernández-Albujar A,Fernández-Rodríguez C,Calvo M,González R,Lozano M,Castellano G,Fernández-Vázquez I

    更新日期:2017-06-01 00:00:00

  • Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.

    abstract::In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly ex...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13339

    authors: Mina M,Underwood A,Eltahla A,Wu BR,Walker MR,Bull RA,Lloyd AR

    更新日期:2020-10-01 00:00:00

  • Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

    abstract::IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. However, their roles in the treatment of chronic HCV genotype 6 remain undetermined. Sixty patients who were...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12047

    authors: Seto WK,Tsang OT,Liu K,Chan JM,Wong DK,Fung J,Lai CL,Yuen MF

    更新日期:2013-07-01 00:00:00

  • Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.

    abstract::It is unknown whether dynamic changes of liver stiffness measurement (LSM) can predict the reversibility of fibrosis. Therefore, we evaluated the utility of LSM changes in predicting histological changes of fibrosis in patients with chronic hepatitis B (CHB) on antiviral therapy. In a prospective cohort of CHB patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13058

    authors: Kong Y,Sun Y,Zhou J,Wu X,Chen Y,Piao H,Lu L,Ding H,Nan Y,Jiang W,Xu Y,Xie W,Li H,Feng B,Shi G,Chen G,Li H,Zheng H,Cheng J,Wang T,Liu H,Lv F,Shao C,Mao Y,Sun J,Chen T,Han T,Han Y,Wang L,Ou X,Zha

    更新日期:2019-05-01 00:00:00

  • Simian hepatitis A virus derived from a captive rhesus monkey in India is similar to the strain isolated from wild African green monkeys in Kenya.

    abstract:SUMMARY:A simian hepatitis A virus (HAV) was identified retrospectively in a faecal sample from a rhesus monkey in India, inoculated in 1995 with a faecal suspension from a suspected patient of non-A to E hepatitis. The monkey was in captivity for 2 years in one of the experimental primate facilities in western India b...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.01060.x

    authors: Arankalle VA,Ramakrishnan J

    更新日期:2009-03-01 00:00:00

  • Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.

    abstract::Viral load reduction facilitates recovery of antiviral T-cell responses. Dynamic alterations in intrahepatic viraemia clearance and immune cell reactivity during the early phase of nucleoside analogue (NA) therapy and the impact of these changes on HBeAg seroconversion are unknown. Fifteen HBeAg-positive chronic hepat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12261

    authors: Zheng Q,Zhu YY,Chen J,Liu YR,You J,Dong J,Zeng DW,Gao LY,Chen LH,Jiang JJ

    更新日期:2014-12-01 00:00:00

  • Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy.

    abstract::In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir > or = F2) is variable. Constitutional and liver disease-related factors may influence TE and here we examined the variables associated with differences. Three hundred consecutiv...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01199.x

    authors: Calvaruso V,Cammà C,Di Marco V,Maimone S,Bronte F,Enea M,Dardanoni V,Manousou P,Pleguezuelo M,Xirouchakis E,Attanasio M,Dusheiko G,Burroughs AK,Craxì A

    更新日期:2010-07-01 00:00:00

  • Natural history of serum HBV-RNA in chronic HBV infection.

    abstract::Virus-like particles encapsulating HBV-RNA represent a serum biomarker for assessing viral replication activity in clinical practice. However, baseline levels of serum HBV-RNA and their associations with viral replicative intermediates and liver disease in phases of chronic hepatitis B remain unknown. In this cross-se...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12908

    authors: Wang J,Yu Y,Li G,Shen C,Li J,Chen S,Zhang X,Zhu M,Zheng J,Song Z,Wu J,Shao L,Meng Z,Wang X,Huang Y,Zhang J,Qiu C,Zhang W

    更新日期:2018-09-01 00:00:00

  • Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.

    abstract::High rates (~25%) of developing chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg)-positive for > 6 months following infection) have been observed in people who use drugs (PWUD) and men who have sex with men (MSM). We aimed to estimate the frequency of delayed HBsAg seroclearance, along wit...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13205

    authors: van Santen DK,Boyd A,Bruisten S,Sonder GJ,Prins M,van Houdt R

    更新日期:2020-01-01 00:00:00

  • Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study.

    abstract::The optimal therapy for patients with chronic hepatitis C who have not responded to interferon (IFN) is still an unsolved issue. The aim of this study was to evaluate the efficacy and tolerability of a high dose of IFN-alpha2a plus amantadine for chronic hepatitis C patients who were non-responders to a previous cours...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2001.00298.x

    authors: Gaeta GB,Stornaiuolo G,Stanzione M,Ascione T,Pasquazzi C,Taliani G,Cimino L,Budillon G,Piccinino F

    更新日期:2001-07-01 00:00:00

  • The molecular basis of hepatitis B e antigen (HBeAg)-negative infections.

    abstract::Hepatitis B e antigen (HBeAg)-negative infections are an unusual form of chronic hepatitis B virus (HBV) infection in which viral replication and liver damage persist despite antibodies against HBeAg. This form of HBV may be associated with fulminant hepatitis. The molecular basis for an HBeAg-minus phenotype has been...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1997.00101.x

    authors: Miyakawa Y,Okamoto H,Mayumi M

    更新日期:1997-01-01 00:00:00

  • Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.

    abstract::The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HI...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1999.t01-1-6120135.x

    authors: Fainboim H,González J,Fassio E,Martínez A,Otegui L,Eposto M,Cahn P,Marino R,Landeira G,Suaya G,Gancedo E,Castro R,Brajterman L,Laplumé H

    更新日期:1999-01-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

    abstract::We compared sustained virological response (SVR) in chronic hepatitis C patients with severe fibrosis treated with pegylated interferon (Peg-IFN) alpha-2b 1.5 microg/kg/week or 0.75 microg/kg/week in combination with ribavirin 800 mg/day for 48 weeks. This was a multicentre randomized controlled study. SVR was observe...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2006.00768.x

    authors: Abergel A,Hezode C,Leroy V,Barange K,Bronowicki JP,Tran A,Alric L,Castera L,Bernard PH,Henquell C,Lafeuille H,Ughetto S,Darcha C,Chevallier M,Martineau N,Dubost S,Randl K,Dhumeaux D,Bommelaer G,Bonny C,French mult

    更新日期:2006-12-01 00:00:00

  • Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma.

    abstract::Approximately 30% of patients with chronic HCV infection have persistently normal ALT levels. Although formerly referred to as 'healthy' or 'asymptomatic' HCV carriers, and thus historically excluded from antiviral treatment, it has now become clear that the majority of these patients have some degree of histological ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2011.01485.x

    authors: Puoti C,Guarisco R,Spilabotti L,Bellis L,Mitidieri Costanza O,Dell' Unto O,Elmo MG

    更新日期:2012-04-01 00:00:00

  • Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.

    abstract::Chronic hepatitis B (CHB) is characterized by an impaired immune response to hepatitis B virus. Among the nucleos(t)ides used in CHB treatment, telbivudine is associated with the highest rates of hepatitis B e antigen (HBeAg) seroconversion rates, which are similar to those observed with pegylated interferon (PegIFN)....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12059

    authors: Wang GQ,Ding YP,Dong YH

    更新日期:2013-04-01 00:00:00

  • Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. Although there is no proven medication for hepatitis E, pegylated interferon-α (IFN-α) has been used as off-label drug for treating HEV. However, the efficacy and molecular mechanisms of how IFN signalling interacts with HEV rem...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12491

    authors: Zhou X,Xu L,Wang W,Watashi K,Wang Y,Sprengers D,de Ruiter PE,van der Laan LJ,Metselaar HJ,Kamar N,Peppelenbosch MP,Pan Q

    更新日期:2016-04-01 00:00:00

  • Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein.

    abstract::Hepatitis A virus (HAV) infection is still an important issue worldwide. A distinct set of viruses encode proteins that enhance viral cap-independent translation initiation driven by an internal ribosome entry site (IRES) and suppress cap-dependent host translation. Unlike cytolytic picornaviruses, replication of HAV ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01221.x

    authors: Kanda T,Gauss-Müller V,Cordes S,Tamura R,Okitsu K,Shuang W,Nakamoto S,Fujiwara K,Imazeki F,Yokosuka O

    更新日期:2010-09-01 00:00:00

  • Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene.

    abstract::Transcription of p21 was activated in hepatitis C virus (HCV) Core-expressing HepG2 cells where its upstream p53 was stabilized. However, this effect was not absolutely required for the activation of p21 by Core, as demonstrated in Hep3B cells. In addition, an opposite effect on the transcription of p21 was observed i...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00434.x

    authors: Kwun HJ,Jang KL

    更新日期:2003-07-01 00:00:00